EORTC Melanoma Group changing daily practice
for cancer patients

Melanoma - Illustration

The EORTC Melanoma Group has recently presented and published new data that has shown improved outcomes for cancer patients. The EORTC 1325 study for patients with high-risk stage III resected melanoma (recurrence of disease following surgical removal of tumour), found that 1-year of therapy with immunotherapy treatment (pembrolizumab) after surgery, significantly prolongs time to disease recurrence or death. Based on these results, pembrolizumab treatment was approved by the European Medicines Agency and Food and Drugs Administration (USA). These significant results were presented at ASCO 2020 (American Society of Clinical Oncology), confirming that the positive effect of this treatment (pembrolizumab) is durable with longer follow-up.

Back to blog

Share This Story

Every month we select one topic to be covered by one of our experts. We’d love to hear from you.



Sign up